Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8+ T-cell responses in melanoma patients

Optimal vaccine strategies must be identified for improving T‐cell vaccination against infectious and malignant diseases. MelQbG10 is a virus‐like nano‐particle loaded with A‐type CpG‐oligonucleotides (CpG‐ODN) and coupled to peptide16–35 derived from Melan‐A/MART‐1. In this phase IIa clinical study, four groups of stage III‐IV melanoma patients were vaccinated with MelQbG10, given (i) with IFA (Montanide) s.c.; (ii) with IFA s.c. and topical Imiquimod; (iii) i.d. with topical Imiquimod; or (iv) as intralymph node injection. In total, 16/21 (76%) patients generated ex vivo detectable Melan‐A/MART‐1‐specific T‐cell responses. T‐cell frequencies were significantly higher when IFA was used as adjuvant, resulting in detectable T‐cell responses in all (11/11) patients, with predominant generation of effector‐memory‐phenotype cells. In turn, Imiquimod induced higher proportions of central‐memory‐phenotype cells and increased percentages of CD127+ (IL‐7R) T cells. Direct injection of MelQbG10 into lymph nodes resulted in lower T‐cell frequencies, associated with lower proportions of memory and effector‐phenotype T cells. Swelling of vaccine site draining lymph nodes, and increased glucose uptake at PET/CT was observed in 13/15 (87%) of evaluable patients, reflecting vaccine triggered immune reactions in lymph nodes. We conclude that the simultaneous use of both Imiquimod and CpG‐ODN induced combined memory and effector CD8+ T‐cell responses.

• Publication year

  2012

• Venue

  European Journal of Immunology

• Publication date

  2012-07-18

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/eji.201142361PMID 22806397PMCID 3549564
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Virus‐like particles induce robust human T‐helper cell responses

  2012cited by this paper
• Vaccination‐induced functional competence of circulating human tumor‐specific CD8 T‐cells

  2012cited by this paper
• The three main stumbling blocks for anticancer T cells.

  2012cited by this paper
• Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

  2011cited by this paper
• Autoimmunity and treatment outcome in melanoma

  2011cited by this paper
• Defining the critical hurdles in cancer immunotherapy

  2011cited by this paper
• Incidence and Intensity of F-18 FDG Uptake After Vaccination With H1N1 Vaccine

  2011cited by this paper
• Intra–Lymph Node Prime-Boost Vaccination against Melan A and Tyrosinase for the Treatment of Metastatic Melanoma: Results of a Phase 1 Clinical Trial

  2011cited by this paper
• Duration of 18F-FDG avidity in lymph nodes after pandemic H1N1v and seasonal influenza vaccination

  2011cited by this paper
• Metabolism, migration and memory in cytotoxic T cells

  2011cited by this paper
• Memory and Effector CD8 T-cell Responses After Nanoparticle Vaccination of Melanoma Patients

  2010cited by this paper
• Cancer-Testis Antigens and Immunosurveillance in Human Cutaneous Squamous Cell and Basal Cell Carcinomas

  2010cited by this paper
• Programming the magnitude and persistence of antibody responses with innate immunity

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Sarcoidosis Induced by Interferon-α in Melanoma Patients: Incidence, Clinical Manifestations, and Management Strategies

  2010cited by this paper
• FDG uptake in axillary lymph nodes after vaccination against pandemic (H1N1)

  2010cited by this paper
• Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns

  2010cited by this paper
• The role of mTOR in memory CD8+ T‐cell differentiation

  2010cited by this paper
• Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells

  2009cited by this paper
• Development of effective vaccines for old mice in a tumor model.

  2009cited by this paper
• Immunotherapy: Vaccine trials in melanoma—time for reflection

  2009cited by this paper
• Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen

  2008cited by this paper
• Immunization With Analog Peptide in Combination With CpG and Montanide Expands Tumor Antigen-specific CD8+ T Cells in Melanoma Patients

  2008cited by this paper
• 18F-FDG uptake at vaccination site

  2008cited by this paper
• Phase 1 Trial of Intranodal Injection of a Melan-A/MART-1 DNA Plasmid Vaccine in Patients With Stage IV Melanoma

  2008cited by this paper
• Adenovirus MART-1–engineered Autologous Dendritic Cell Vaccine for Metastatic Melanoma

  2008cited by this paper
• Nanoparticles target distinct dendritic cell populations according to their size

  2008cited by this paper
• Immunization of Malignant Melanoma Patients with Full-Length NY-ESO-1 Protein Using TLR7 Agonist Imiquimod as Vaccine Adjuvant1

  2008cited by this paper
• Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.

  2008cited by this paper
• Phase I Clinical Study With Multiple Peptide Vaccines in Combination With Tetanus Toxoid and GM-CSF in Advanced-stage HLA-A*0201-positive Melanoma Patients

  2007cited by this paper
• Decreased specific CD 8 + T cell cross-reactivity of antigen recognition following vaccination with MelanA peptide

  2006cited by this paper
• Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.

  2006cited by this paper
• False-positive axillary lymph node on FDG-PET/CT scan resulting from immunization.

  2006cited by this paper
• Immunologic and Clinical Effects of Injecting Mature Peptide-Loaded Dendritic Cells by Intralymphatic and Intranodal Routes in Metastatic Melanoma Patients

  2006cited by this paper
• Decreased specific CD8+ T cell cross‐reactivity of antigen recognition following vaccination with Melan‐A peptide

  2006cited by this paper
• Induction of strong and persistent MelanA/MART‐1‐specific immune responses by adjuvant dendritic cell‐based vaccination of stage II melanoma patients

  2006cited by this paper
• Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment.

  2005cited by this paper
• MAGE-A1-, MAGE-A10-, and gp100-Derived Peptides Are Immunogenic When Combined with Granulocyte-Macrophage Colony-Stimulating Factor and Montanide ISA-51 Adjuvant and Administered as Part of a Multipeptide Vaccine for Melanoma1

  2005cited by this paper
• Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

  2005cited by this paper
• Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA.

  2004cited by this paper
• Cancer immunotherapy: moving beyond current vaccines

  2004cited by this paper
• Ex Vivo Analysis of Human Antigen-Specific CD8+ T-Cell Responses: Quality Assessment of Fluorescent HLA-A2 Multimer and Interferon-γ ELISPOT Assays for Patient Immune Monitoring

  2004cited by this paper
• Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma.

  2004cited by this paper
• Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells.

  2003cited by this paper
• Anatomical loci of HIV-associated immune activation and association with viraemia.

  2003cited by this paper
• Two subsets of memory T lymphocytes with distinct homing potentials and effector functions

  1999cited by this paper
• Immune escape mechanisms in malignant melanoma.

  1999cited by this paper
• Two subsets of memory T lymphocytes with distinct homing potentials and effector functions

  1999cited by this paper
• Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distribution

  1998cited by this paper

• Virus-like particles based on plant viruses and bacteriophages: emerging strategies for the delivery of nucleic acid therapeutics

  2026cites this paper
• The application of nanomaterials in vaccine adjuvants

  2026cites this paper
• In vivo imaging of the immune system

  2026cites this paper
• Challenges and opportunities on achieving an adequate delivery efficiency and immunogenicity with peptide-based anticancer vaccines.

  2025cites this paper
• Broad-spectrum vaccines against various and evolving viruses: from antigen design to nanoparticle delivery

  2025cites this paper
• VLP (Virus-Like Particles) Vaccines - Current Knowledge and Future Directions

  2025cites this paper
• Virus-like particle: a nano-platform that delivers cancer antigens to elicit an anti-tumor immune response

  2025cites this paper
• Melanoma immunotherapy by nanosphere-vaccine elicited CD4+ and CD8+ T-cell response for tumor regression.

  2025cites this paper
• Investigation of plant virus-like particle formation in bacterial and yeast expression systems

  2024cites this paper
• Engineering nanoparticles for cancer immunotherapy: Current achievements, key considerations and future perspectives

  2024cites this paper
• Peptide nanovaccine in melanoma immunotherapy.

  2024cites this paper
• A phase 1 trial of human telomerase reverse transcriptase (hTERT) vaccination combined with therapeutic strategies to control immune-suppressor mechanisms

  2024cites this paper
• Co-Delivery of a Novel Lipidated TLR7/8 Agonist and Hemagglutinin-Based Influenza Antigen Using Silica Nanoparticles Promotes Enhanced Immune Responses

  2024cites this paper
• Poly(I:C) and R848 ligands show better adjuvanticity to induce B and T cell responses against the antigen(s)

  2024cites this paper
• Peptide Vaccines in Melanoma: Chemical Approaches towards Improved Immunotherapeutic Efficacy

  2023cites this paper
• Supramolecular assembly of a trivalent peptide hydrogel vaccine for cancer immunotherapy.

  2023cites this paper
• Mechanisms and influencing factors of peptide hydrogel formation and biomedicine applications of hydrogels.

  2023cites this paper
• Protein-Based Nanocarriers and Nanotherapeutics for Infection and Inflammation

  2023cites this paper
• Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy

  2023cites this paper
• Viral protein-based nanoparticles (Part 2): Pharmaceutical applications.

  2023cites this paper
• Nanoparticle-based immunotherapeutics: from the properties of nanocores to the differential effects of administration routes.

  2023cites this paper
• Nanoparticles as a Therapeutic Delivery System for Skin Cancer Prevention and Treatment

  2023cites this paper
• "Open Sesame" to the complexity of pattern recognition receptors of myeloid-derived suppressor cells in cancer

  2023cites this paper
• Novel Therapeutic Approaches Targeting Post-Translational Modifications in Lung Cancer

  2023cites this paper
• Fueling Cancer Vaccines to Improve T Cell-Mediated Antitumor Immunity

  2022cites this paper
• Targeting the innate immune system with nanoparticles for cancer immunotherapy.

  2022cites this paper
• Self‐Assembly of Immune Signals to Program Innate Immunity through Rational Adjuvant Design

  2022cites this paper
• Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation

  2022cites this paper
• Advances in Nanotechnology for Cancer Immunoprevention and Immunotherapy: A Review

  2022cites this paper
• Peptide emulsions in incomplete Freund’s adjuvant create effective nurseries promoting egress of systemic CD4+ and CD8+ T cells for immunotherapy of cancer

  2022cites this paper
• MuSyC dosing of adjuvanted cancer vaccines optimizes antitumor responses

  2022cites this paper
• Nanotechnology‐facilitated vaccine development during the coronavirus disease 2019 (COVID‐19) pandemic

  2022cites this paper
• Recent advances in cancer immunotherapy: Modulation of tumor microenvironment by Toll-like receptor ligands

  2022cites this paper
• Protein Cages: From Fundamentals to Advanced Applications.

  2022cites this paper
• Bedside formulation of a personalized multi-neoantigen vaccine against mammary carcinoma

  2021cites this paper
• Immunization with short peptide particles reveals a functional CD8+ T-cell neoepitope in a murine renal carcinoma model

  2021cites this paper
• Dermal and Transdermal Drug Delivery through Vesicles and Particles: Preparation and Applications

  2021cites this paper
• ROS Cocktails as an Adjuvant for Personalized Antitumor Vaccination?

  2021cites this paper
• Multifunctional biomolecule nanostructures for cancer therapy

  2021cites this paper
• Self-assembled peptide and protein nanostructures for anti-cancer therapy: Targeted delivery, stimuli-responsive devices and immunotherapy.

  2021cites this paper
• Development of CpG oligodeoxynucleotide TLR9 agonists in anti-cancer therapy

  2021cites this paper
• An Overview of Nanocarrier-Based Adjuvants for Vaccine Delivery

  2021cites this paper
• The Use of Nanobiotechnology in Immunology and Vaccination

  2021cites this paper
• DNA Vaccines: Methods and Protocols

  2021cites this paper
• Engineering Nanoparticles toward the Modulation of Emerging Cancer Immunotherapy

  2020cites this paper
• TLR7 and RIG-I dual-adjuvant loaded nanoparticles drive broadened and synergistic responses in dendritic cells in vitro and generate unique cellular immune responses in influenza vaccination

  2020cites this paper
• Lipid Nanoparticles Potentiate CpG-Oligodeoxynucleotide-Based Vaccine for Influenza Virus

  2020cites this paper
• Synthesis of protein conjugates adsorbed on cationic liposomes surface

  2020cites this paper
• Nanoparticles to Improve the Efficacy of Peptide-Based Cancer Vaccines

  2020cites this paper
• Interaction Between Virus-Like Particles (VLPs) and Pattern Recognition Receptors (PRRs) From Dendritic Cells (DCs): Toward Better Engineering of VLPs

  2020cites this paper
• RAFT/PISA based Ni-NTA polymeric particles for virus-mimetic influenza vaccines

  2020cites this paper
• Nanomedicine-mediated alteration of the pharmacokinetic profile of small molecule cancer immunotherapeutics.

  2020cites this paper
• Active Delivery of VLPs Promotes Anti-Tumor Activity in a Mouse Ovarian Tumor Model.

  2020cites this paper
• OTT_A_247050 10039..10060

  2020cites this paper
• The 3Ds in virus‐like particle based‐vaccines: “Design, Delivery and Dynamics”

  2020cites this paper
• Harnessing the immune system to fight cancer with Toll-like receptor and RIG-I-like receptor agonists.

  2020cites this paper
• Nutrition, Immunity and Viral Infections

  2020cites this paper
• The biomedical and bioengineering potential of protein nanocompartments.

  2020cites this paper
• Biogenic nanoparticles as immunomodulator for tumor treatment.

  2020cites this paper
• Design of a novel vaccine nanotechnology-based delivery system comprising CpGODN-protein conjugate anchored to liposomes.

  2020cites this paper
• Recent Progress on the Versatility of Virus-Like Particles

  2020cites this paper
• Nanomedicine-mediated alteration of the pharmacokinetic profile of small molecule cancer immunotherapeutics

  2020cites this paper
• Integrated Process for Capture and Purification of Virus-Like Particles: Enhancing Process Performance by Cross-Flow Filtration

  2020cites this paper
• Shaping Modern Vaccines: Adjuvant Systems Using MicroCrystalline Tyrosine (MCT®)

  2020cites this paper
• Toll‐like receptors (TLRs) in cancer; with an extensive focus on TLR agonists and antagonists

  2020cites this paper
• The Role of Virus-Like Particles in Medical Biotechnology.

  2020cites this paper
• Toll-Like Receptor 9 Agonists in Cancer

  2020cites this paper
• The magic bullet as cancer therapeutic—has nanotechnology failed to find its mark?

  2020cites this paper
• CpG Oligonucleotides as Vaccine Adjuvants.

  2020cites this paper
• Nanoparticles: Properties and Applications in Cancer Immunotherapy.

  2019cites this paper
• The Role of Nanovaccine in Cross-Presentation of Antigen-Presenting Cells for the Activation of CD8+ T Cell Responses

  2019cites this paper
• Toll-like receptor-targeted particles: A paradigm to manipulate the tumor microenvironment for cancer immunotherapy.

  2019cites this paper
• Carbon Nanostructures in Cancer Diagnosis and Therapy

  2019cites this paper
• Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Efficacy of an Instantly Formulated Cancer Nano-Vaccine

  2019cites this paper
• Materials for Immunotherapy

  2019cites this paper
• Early Transcriptional Signature in Dendritic Cells and the Induction of Protective T Cell Responses Upon Immunization With VLPs Containing TLR Ligands—A Role for CCL2

  2019cites this paper
• Virus‐like particles for vaccination against cancer

  2019cites this paper
• Cooperation of Oligodeoxynucleotides and Synthetic Molecules as Enhanced Immune Modulators

  2019cites this paper
• Vaccination with nanoparticles combined with micro-adjuvants protects against cancer

  2019cites this paper
• Protein-based nanoparticles in cancer vaccine development.

  2019cites this paper
• Immunomodulatory Nanosystems

  2019cites this paper
• Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies

  2019cites this paper
• Application of built-in adjuvants for epitope-based vaccines

  2019cites this paper
• Particulate carrier systems as adjuvants for cancer vaccines.

  2019cites this paper
• Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication

  2019cites this paper
• Using FRET to measure the time it takes for a cell to destroy a virus.

  2019cites this paper
• Advancing Cancer Immunotherapies with Nanotechnology

  2019cites this paper
• Polymer-based nanoparticles loaded with a TLR 7 ligand to target the lymph node for immunostimulation WIDMER , Jérôme

  2018cites this paper
• Immunization Strategies Producing a Humoral IgG Immune Response against Devil Facial Tumor Disease in the Majority of Tasmanian Devils Destined for Wild Release

  2018cites this paper
• Polymer-based nanoparticles loaded with a TLR7 ligand to target the lymph node for immunostimulation.

  2018cites this paper
• Enhancing the Safety and Efficacy of Food Allergy Immunotherapy: a Review of Adjunctive Therapies

  2018cites this paper
• Interaction of Viral Capsid-Derived Virus-Like Particles (VLPs) with the Innate Immune System

  2018cites this paper
• Self-Assembly of Immune Signals Improves Codelivery to Antigen Presenting Cells and Accelerates Signal Internalization, Processing Kinetics, and Immune Activation.

  2018cites this paper
• Delivering all in one: Antigen‐nanocapsule loaded with dual adjuvant yields superadditive effects by DC‐directed T cell stimulation

  2018cites this paper
• Recent advances in applying nanotechnologies for cancer immunotherapy

  2018cites this paper
• Nanoparticle Vaccines Against Infectious Diseases

  2018cites this paper
• Rickettsia rickettsii Whole-Cell Antigens Offer Protection against Rocky Mountain Spotted Fever in the Canine Host

  2018cites this paper
• Plant viral and bacteriophage delivery of nucleic acid therapeutics.

  2018cites this paper
• Immunomodulation with Adjuvants and Cytokines

  2018cites this paper
• Nanoscale delivery systems for cancer immunotherapy

  2018cites this paper